UPDATE: The FDA announced that it will push back its decision on whether to approve the reversal agent AndexXa to May 4, 2018. The original review date was set for February 3, 2018, but the FDA wanted to consider additional information it had requested from Portola, the drug's manufacturer. (12/28/17). Risk of Bleeding … [Read more...]
New Anticoagulant BevyxXa Approved by the FDA
On June 23, 2017, a new anticoagulant drug called BevyxXa (betrixaban) was approved by the FDA for the prevention of venous thromboembolism and pulmonary embolism. This drug acts as a direct Factor Xa inhibitor, similar to the other anticoagulant drugs Eliquis, Savaysa, and Xarelto. Unlike the anticoagulant Pradaxa, which is a direct … [Read more...]
Eliquis MDL For Federal Lawsuits; In California, JCCP Petition Pending
In the federal court system, there are now more than 50 Eliquis lawsuits filed, and more of these drug injury and death cases are expected. Given this situation, in early February 2017 the United States Judicial Panel on Multidistrict Litigation (JPML) established this consolidation of all federal court Eliquis cases, IN RE: ELIQUIS (APIXABAN) … [Read more...]
Defendants BMS And Pfizer Ask For Eliquis Federal Court Consolidation
On October 13, 2016 attorneys for Bristol-Myers Squibb Company and Pfizer Inc. filed with the United States Judicial Panel on Multidistrict Litigation (JPML) this court document, “BRISTOL-MYERS SQUIBB COMPANY AND PFIZER INC.’S MOTION FOR TRANSFER OF RELATED ELIQUIS (APIXABAN) PRODUCTS LIABILITY ACTIONS FOR COORDINATED PRETRIAL PROCEEDINGS PURSUANT … [Read more...]
Warfarin vs. Eliquis, Pradaxa, Xarelto, and Savaysa: Which is Better?
There in an ongoing debate amongst medical professionals concerning the effectiveness and safety of warfarin in comparison to the non–vitamin K antagonist oral anticoagulants (NOACs)--such as Eliquis, Xarelto, Savaysa, and Pradaxa--for patients with atrial fibrillation. According to the Healio Cardiology today article, "Merits of warfarin, newer … [Read more...]
Is Eliquis A Safe Alternative To Warfarin For Patients On Dialysis?
In this article published online by Pharmacy Times in August 2016, “Is Apixaban Safe and Effective for Patients on Hemodialysis?”, Brandon Dyson, PharmD, BCPS, who is a clinical pharmacist at an academic medical center, puts some scrutiny on Eliquis, an increasingly popular blood-thinner drug: [Eliquis (apixaban)] is the only [novel oral … [Read more...]
No Clinical Trials Comparing The Safety Of Eliquis To Xarelto Done Yet
In two medical study reports it seemed that Xarelto (rivaroxaban) was more likely to be involved in a serious bleeding event as an adverse reaction than was either Pradaxa (dabigatran) or Eliquis (apixaban). Earlier this month the medical journal Chest published this article, “Direct comparison of dabigatran, rivaroxaban, and apixaban for … [Read more...]
What’s in a Name? Debate on What to Call Novel Oral Anticoagulants
Recently, controversy has arisen over what to call the novel oral anticoagulant class of drugs, which includes Pradaxa, Xarelto, Savaysa, and Eliquis. The article "NOAC, DOAC, or TSOAC: What Should We Call Novel Oral Anticoagulants?" provides some interesting information about the different sides of this debate. Here is a list of the possible … [Read more...]
Eliquis Lawsuits Being Filed Across The Country In Increasing Numbers
It is important to know that as of September 2016 Eliquis does not currently have an FDA-approved antidote, or reversal agent, for a patient experiencing a trauma-induced bleeding event or needing emergency surgery. Eliquis (apixaban) was approved by the FDA in December 2012. These serious medical conditions have been associated with the use of … [Read more...]
Antidote Drug For Xarelto / Savaysa / Eliquis Is Denied FDA Approval
The following Factor Xa inhibitors, which serve as blood-thinner drugs, are being used by an increasing number of patients for stroke prevention and for treatment of deep vein thrombosis and pulmonary embolism: Eliquis (apixaban) from Pfizer/Bristol-Myers Squibb; Xarelto (rivaroxaban) from Bayer/Johnson & Johnson; and, Savaysa … [Read more...]